News

Testosterone After Prostate Surgery: What SPIRIT Found

The SPIRIT trial has added randomized evidence to a difficult question: can selected men with testosterone deficiency receive replacement therapy after prostate cancer surgery? Its results show short-term improvements in several measures of sexual and physical function, alongside a clear limit on what a small trial can establish about cancer safety.

From the Journal Report to Posted Trial Results

JAMA Internal Medicine first published the research online in May and included it in its July 2026 issue. ClinicalTrials.gov posted the trial's results on July 16. The study involved 136 men who had undergone radical prostatectomy for organ-confined, low-grade cancer and had undetectable PSA for at least two years.

Participants also had symptoms and repeatedly low testosterone. Researchers assigned them to weekly testosterone injections or placebo for 12 weeks. Testosterone improved sexual activity, desire, and several physical outcomes. Erectile function did not improve. No participant experienced the study's defined biochemical recurrence during follow-up, but the authors say the trial cannot establish long-term cancer safety.

The Trial Asked a Narrow Question

The registration identifies SPIRIT as a randomized, masked supportive-care study. Investigators selected patients with a particular cancer history and hormone profile, then compared treatment with placebo. That design helps answer whether testosterone can improve specified symptoms in this group. It does not test unsupervised treatment or every group of prostate cancer survivors.

The posted trial record also lets readers compare the planned study with the reported results. It identifies the intervention, allocation, enrollment, and outcomes. For a patient reading about a new treatment, those details can reveal whether a study involved men with a history like his own or a population that differs in a way that affects the decision.

Sexual Desire and Erection Firmness Did Not Move Together

The research team's announcement describes improvements in desire, sexual activity, well-being, body composition, and exercise-related measures. It also states that erection function did not change. This distinction matters when deciding what someone means by a treatment that improves sexual health.

A man may want more interest in sex, more reliable erections, less fatigue, or a return to specific activities. Those goals overlap, but a result for one does not prove a result for the others. The SPIRIT findings support a discussion about symptom targets. They do not support promising that testosterone will reverse ED after prostate surgery.

Why Surgery Can Leave Several Different Problems

The American Cancer Society explains that prostate surgery can affect the nerves and blood vessels involved in erections. Recovery varies with the operation, previous erectile function, age, and other health factors. Removing the prostate also changes ejaculation, even when a man can experience orgasm.

That background helps explain why a hormone result cannot describe the entire postoperative picture. A survivor may need a discussion of erection treatments, changes in orgasm or ejaculation, bladder symptoms, and the emotional effect of cancer treatment. A request for help with sex should give him room to describe each concern rather than reduce the conversation to a blood test.

A Short Trial Cannot Settle a Long-term Safety Question

No observed recurrence during a limited study differs from proof that recurrence risk remains unchanged over many years. The investigators explicitly call for a larger, longer trial. Their report also excludes applying these findings to men with high-grade disease or men who received radiation or androgen deprivation therapy.

For someone considering treatment after cancer surgery, the useful discussion begins with his pathology, PSA history, symptoms, and previous care. He should ask how his case compares with the trial criteria and what monitoring the treating clinicians would require. A headline cannot supply those answers.

Decide Which Outcome You Want to Track

A survivor may reasonably describe treatment as helpful if desire returns, even when he still needs another approach for erections. Another may regard that same outcome as insufficient because reliable firmness remains his priority. Naming the target before treatment makes that difference explicit.

Ask how you would record the result without turning intimacy into a daily test. A short account of activity, desire, fatigue, and adverse effects may help the follow-up discussion. The plan should also identify who will coordinate cancer surveillance and hormone-related monitoring, so each clinician understands the other part of the care.

Preparing for a Consultation After Cancer Treatment

Bring the operation date, pathology report if available, recent PSA results, hormone tests, and a list of current medicines. Describe what changed after treatment and which concern now affects your quality of life most. Ask the clinician to separate evidence for symptom benefit from evidence about cancer safety.

Also ask how the plan would change if desire improves but erection firmness does not. Our ED treatment overview covers medication and other options, while the low testosterone section explains the assessment to discuss before hormone treatment.

Sources

Comments

Leave a comment